AB1197 EFFECTS AND SAFETY OF THE YELLOW FEVER VACCINE 17DD IN PATIENTS WITH IMMUNOMEDIATED RHEUMATIC DISEASES
Authors: Blanca Bica, Lucas Peixoto Da Silva, Gecilmara Salviato Pileggi
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background</h3> The yellow fever is an acute infectious disease caused by the amarilic virus. It is present in tropical areas of South America and Africa and is transmitted to humans through the bites of the infected female mosquitos, found in the endemic forest zones. The vaccine is produced with attenuated viruses and represents an essential prevention method. It confers prolonged immune protection and is considered to be safe in the general population. For the immunosuppressed condition under which many patients with immunomediated rheumatic diseases (IMRD) are submitted, little is known about its efficacy and safety in this group. <h3>Objectives</h3> The aim of this study is to analyse the effects of the vaccine in patients with IMRD. <h3>Methods</h3> The methodology of this research consisted of the application of a form-based interview, the analyses of the vaccine card and medical records, if existent. The requirement to take part as a volunteer was to be an IMRD patient that was vaccinated against yellow fever. <h3>Results</h3> 60 ambulatorial patients, unadvisedly vaccinated or not, were evaluated. Of those, 40 (66.7%) were female and 20 (33.3%) were male, with an age range varying from 8 to 48 years. It was observed that 52 (86.7%) presented no adverse effects from the vaccine, while 7 (11.7%) presented at least one side effect and 1 (1.7%) exhibited a severe reactivation of the underlying rheumatic disease. In the group of 7 patients that registered any side effects, it was described 1 case of bilateral optic neuritis with temporary vision loss, initiated three weeks after the vaccination. The other side effects registered were mild and included: 3 occurrences of headache and 1 record of each of the following: fever, local pain, arthralgia, myalgia, nausea, coryza and diarrhea. <h3>Conclusion</h3> Our data suggested that the vaccine exhibits a relative degree of safety in these patients. The benefits of the immunization should be evaluated by the rheumatologist, taking in account the risk of infection and lethality of yellow fever in patients who live or are visiting the endemic areas. The recommendations are that the vaccination in this group must always be planned, done under medical orientation and order. It should preferably be applied in patients under disease remission, without immunosuppression treatment or in those who, under immunosuppressors, it is possible to temporarily suspend this treatment in order to the vaccine to be administered. <h3>References</h3> [1] J. ERIN STAPLES, MD1; JOSEPH A. BOCCHINI JR., MD2,3; LORRY RUBIN, MD2,4; MARC FISCHER, MD. Yellow Fever Vaccine Booster Doses: Recommendations of the Advisory Committee on Immunization Practices, 2015 Morbidity and Mortality Weekly Report MMWR/June 19, 2015/Vol. 64/No. 23 [2] TANRIöVER M.D. da. et al. Vaccination recommendations for adult patients with rheumatic diseases European Journal of Rheumatology. 2016; 3: 29-35 <h3>Disclosure of Interests</h3> None declared